Sharron McCulloch became the Vice President of Clinical Operations at Britecyte in January 2024. Prior to joining Britecyte, Sharron spent 20 years at Osiris Therapeutics, a leader in the regenerative medicine space. During her tenure at Osiris Therapeutics, Sharron held numerous leadership positions most recently serving as the Senior Director of Medical & Clinical Affairs, delivering strategic planning and oversight for scientific and clinical medical affairs programs alongside cross-functional teams. In this role, she had direct involvement with several studies resulting in peer-reviewed publications describing the clinical and commercial applications of tissue-based products across various indications, providing critical evidence for obtaining market access and reimbursement. Sharron was instrumental in helping to develop and provide oversight in all phases of the multi-center clinical trials. Earlier in her career, she played a key role in the development and launch of Osteocel®, the world’s first bone allograft containing native mesenchymal stem cells. In 2019, Osiris was acquired by Smith+Nephew, a global medical technology business, where Sharron further expanded her clinical experience as the Director of US Global Clinical Operations for medical device studies.
Sharron earned a BS degree in Biology from Gettysburg College and a MS degree in Biotechnology from the Johns Hopkins University. Additionally, she is a Certified Clinical Research Professional (CCRP) by the Society of Clinical Research Associates (SOCRA).